The potential opioid replacement for back pain is gene therapy that regrows the worn-out spinal disc behind the pain. The new study delivered it right into the disc inside extracellular vesicles. These tiny carriers are much safer than genetically modified viruses.
Chronic back pain from a worn-out disc is hard to treat. But regenerative medicine is moving forward. Gene therapy may help a disc rebuild itself. The hard part is getting it to the disc. Millions of people in the US live with chronic pain syndromes like back pain. It is hard to treat. It also tends to come back. Drugs like opioids may dull pain, but they are not the cure. And long-term opioid use is associated with many health risks. The same is true for other drugs. So we need a better treatment for back pain. Why is chronic back pain so hard to treat? Because the problem has many parts. It can come from wear in the spinal disc, mood disorders, and other causes. In many people, a worn-out disc is the cause of constant pain. So many patients may gain from treatment that helps the disc regrow. Such a treatment would also beat surgery, which often fails to relieve pain. In recent years, researchers have tested many regenerative therapies, like gene therapy. But getting the gene therapy into place is still hard. Genetically modified viruses may do it, but that method is associated with some health risks. In the new therapy, published in Biomaterials, researchers used tiny carriers (nanocarriers) to bring modified genes to the target. These carriers were modified extracellular vesicles. The body already uses these small packets to move active compounds and to pass messages between cells.
How does gene therapy repair a degenerated spinal disc?
Researchers showed that engineered extracellular vesicles (EVs) can repair worn tissue in mouse intervertebral disc (IVD) joints. The EVs carried genetic material: a developmental transcription factor (a gene switch) called FOXF1. This minimally invasive approach may help treat degenerative back pain (DBP). This was among the first studies to use engineered EVs (eEVs) to deliver transcription factors in a living animal. Earlier research tried EVs taken from progenitor cells, like mesenchymal stem cells (MSCs), for muscle and bone therapies. But those EVs often run into problems in the clinic, because the cells are hard to collect, might feed tumor growth, and might cause autoimmune diseases. EVs from sources like fibroblasts (common connective tissue cells) are easier to get and free of those risks. Non-viral carriers like eEVs beat viral methods in several ways. They are safer, cause less immune reaction, and can carry many kinds of cargo. That makes eEVs fit for repeat use, especially in some chronic pain that needs long treatment. The team had already reprogrammed human IVD cells in the lab dish (in vitro). They used transcription factors Brachyury and FOXF1 and non-viral transfection methods. Those methods have limits for real disc treatment. So this study tested eEVs in living mice (in vivo) to deliver FOXF1 to worn discs. FOXF1-loaded eEVs significantly improved both the build and the function of worn discs compared to controls. Discs held more water, gained height, and had more proteoglycan. Proteoglycan is a key building block of a healthy disc. Spine function also got better. The mice moved more and had less disability.
The Bottom Line
The research shows eEVs could be used to deliver genes in regenerative medicine. Developmental transcription factors inside eEVs can directly reprogram the body’s own worn disc cells, which reduces pain. More studies must compare eEVs with other non-viral methods and test how well they work over the long term. Still, this study makes a strong case for eEVs as a treatment for DBP and maybe other joint disorders. If you are dealing with chronic pain, you may visit Padda Institute for expert consultation and personalized treatment.
Frequently asked questions
What new treatment could replace opioids for back pain?
The candidate in this study is gene therapy that regrows the worn-out spinal disc behind the pain. Researchers packed a gene switch called FOXF1 into engineered extracellular vesicles. They put it straight into worn discs. In mice, the discs held more water, gained back height and rebuilt proteoglycan. The animals moved better with less disability.
Why aren’t opioids the answer for chronic back pain?
Opioids can turn down pain, but they do not fix what causes it. Long-term use carries real health risks. Other drugs have the same problem. Surgery often fails to relieve the pain, too. When a worn disc is the source of constant pain, a treatment that regrows the disc goes after the cause instead.
Why deliver gene therapy in extracellular vesicles instead of viruses?
Genetically modified viruses can carry genes into cells, but they come with health risks. Extracellular vesicles are packets the body already uses to move active compounds and pass messages between cells. Engineered ones made from fibroblasts are safer. They cause less immune reaction and can be given again and again. That matters for chronic pain that needs long treatment.
Is disc gene therapy available to patients now?
This is still research. The study was among the first to use engineered vesicles in a living animal, and it was done in mice. The researchers say more studies must compare this method with other non-viral methods. They must also test how well it works over the long term before it becomes a treatment for people.
Source: Tang, S. N., Salazar-Puerta, A. I., Heimann, M. K., Kuchynsky, K., Rincon-Benavides, M. A., Kordowski, M., Gunsch, G., Bodine, L., Diop, K., Gantt, C., Khan, S., Bratasz, A., Kokiko-Cochran, O., Fitzgerald, J., Laudier, D. M., Hoyland, J. A., Walter, B. A., Higuita-Castro, N., & Purmessur, D. (2024). Engineered extracellular vesicle-based gene therapy for the treatment of discogenic back pain. Biomaterials, 308, 122562. https://doi.org/10.1016/j.biomaterials.2024.122562
Related reading on painmd.tv
Dr. Gurpreet Singh Padda, MD, MBA, MHP
